Top Section/Ad
Top Section/Ad
Most recent
French biotech seeks to accelerate cancer vaccine program
Payment processor's shares dropped to new low on Thursday
More articles/Ad
More articles/Ad
More articles
-
-
Gimv completes €247m rights issue
-
Share price bounces 7.5% as investors digest 13 for 20 deal
-
Doubts linger over IPO market but some hope 2025 will be the year of sell-downs
-
Major shareholders underwrite the deal
-
Deal to help Peach tackle next year’s bond maturity